Biogen to seek FDA approval for Alzheimer's drug Aducanumab

Biogen is planning to file for U.S. regulatory approval for its Alzheimer's treatment after fresh analysis of its clinical trial showed promise, the drugmaker said. CNBC's Meg Tirrell Reports.